

SeaBeLife Biotech
Onglets principaux
À propos de votre organisation / profil
SeaBeLife pioneers a revolutionary therapeutic paradigm aimed at halving the medical burden, including mortality rates, of severe pathologies lacking effective treatments. Our strategy focuses on developing First-In-Class small Drugs, rooted in a proprietary platform technology comprising small molecules that halt cellular death and forestall organ failure. With a robust pipeline boasting 150 patented molecules exclusively licensed to SeaBeLife, our innovative approach targets critical medical needs. Currently, we are advancing two assets through preclinical development: SBL01, designed to address life-threatening Orphan and Acute Liver Injuries / Failures (ALI/ALF), and SBL03, aiming to preserve vision in Dry-AMD patients, a leading cause of blindness globally among the elderly. These initiatives promise to transform patient outcomes, addressing significant social, economic, and healthcare challenges.
Réseau (0)
Il n'y a pas encore d'organisations dans le réseau.
Activités récentes

SeaBeLife Biotech a mis hors ligne une levée de fond levée de fonds.

La dataroom a été mise à jour.

Le document de type pitchdeck a été mis à jour dans la dataroom.

SeaBeLife Biotech a mis à jour sa levée de fonds.

SeaBeLife Biotech a publié une levée de fonds.

Morgane Rousselot a rejoint SeaBeLife Biotech.